Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.

Robin Joyce(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Daire J. Hurley(Mater Misericordiae University Hospital), J C Tetrealt, C N Kraser, Nancy Giallombardo(Beth Israel Deaconess Medical Center), T Umiel, David F. McDermott(Beth Israel Deaconess Medical Center), J Levine, Meredith M. Regan(Dana-Farber Cancer Institute)
PubMed
July 1, 2001
Cited by 5

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k